<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988997</url>
  </required_header>
  <id_info>
    <org_study_id>NMSBS01-002</org_study_id>
    <nct_id>NCT04988997</nct_id>
  </id_info>
  <brief_title>VIBRANT Study of Vurolenatide in Adult Patients With Short Bowel Syndrome.</brief_title>
  <official_title>A Phase 2, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study of the Efficacy, Safety, and Tolerability of Vurolenatide in Adult Patients With Short Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>9 Meters Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>9 Meters Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study of Vurolenatide in Adult Patients with Short Bowel Syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 2 study of Vurolenatide in adult patients with SBS. A total of 22 patients are&#xD;
      planned to be dosed in four treatment groups with placebo and/or active Vurolenatide. The&#xD;
      study is 13 weeks (3 weeks screening, 4 weeks SC study drug administration, and 6 weeks of&#xD;
      follow up). Safety and efficacy will be analyzed. Information on patients reported outcomes&#xD;
      (ePRO) will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Double-Blind, Double-Dummy, Placebo-Controlled.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-Blind, Double-Dummy, Placebo-Controlled.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>24hr total stool output volume</measure>
    <time_frame>10 weeks (including 6 weeks follow up)</time_frame>
    <description>The primary outcome measure is 24hr total stool output volume over the double-blind treatment period compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety and tolerability of vurolenatide</measure>
    <time_frame>10 weeks (including 6 weeks follow up)</time_frame>
    <description>Assessment of Adverse events - The frequency of spontaneously reported AEs will be assessed for each treatment group separately by System Organ Class and Preferred Term; and vital signs, physical examination results, clinical laboratory tests results will evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess change from Baseline in Quality of Life</measure>
    <time_frame>10 weeks (including 6 weeks follow up)</time_frame>
    <description>Change from baseline in Quality of Life as measured by the SF-36 instrument over the double-blind treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the change from baseline in Patient Global Impression</measure>
    <time_frame>10 weeks (including 6 weeks follow up)</time_frame>
    <description>Change from baseline in patient reported global SBS improvement over the double-blind treatment period</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Vurolenatide 50 mg/PBO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg biweekly SC administration, PBO alternate weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vurolenatide 100 mg/PBO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg biweekly SC administration, PBO alternate weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vurolenatide 50/50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg weekly SC administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PBO - weekly SC administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vurolenatide 50mg/PBO</intervention_name>
    <description>Vurolenatide - 50 mg biweekly SC administration, PBO alternate weeks</description>
    <arm_group_label>Vurolenatide 50 mg/PBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vurolenatide 100mg/PBO</intervention_name>
    <description>Vurolenatide - 100 mg biweekly SC administration, PBO alternate weeks</description>
    <arm_group_label>Vurolenatide 100 mg/PBO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vurolenatide 50/50 mg</intervention_name>
    <description>Vurolenatide - 50 mg weekly SC administration</description>
    <arm_group_label>Vurolenatide 50/50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PBO - weekly SC administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Criteria for patient inclusion in this study are as follows:&#xD;
&#xD;
          1. Male and female adults with SBS secondary to surgical resection of small intestine&#xD;
&#xD;
          2. 18-75 years of age at the time of screening.&#xD;
&#xD;
          3. Female patients must be postmenopausal (at least 2 years prior to dosing) or&#xD;
             surgically sterile or agree to use an acceptable form of birth control from screening&#xD;
             until 30 days after last dose. If oral contraceptives are used, patients must have&#xD;
             been on a stable dose for ≥6 months.&#xD;
&#xD;
          4. Male patients must agree to use an acceptable form of birth control during the study&#xD;
             and for 30 days after the last dose. Male patients should not donate sperm for 90 days&#xD;
             after last dose.&#xD;
&#xD;
          5. At least 6 months since last surgical bowel resection.&#xD;
&#xD;
          6. Patients may be on Parenteral Support [PS] (nutrition and/or fluid and electrolytes&#xD;
             for at least some of their nutritional needs).&#xD;
&#xD;
          7. If on PS, stable administration of PS volume for 1 month (±20% vol) prior to&#xD;
             enrollment [stable administration of PS volume confirmed by Medical Monitor].&#xD;
&#xD;
          8. Able to ingest solid or semi-solid foods and drink.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Criteria for exclusion from participation in this study are presented below. If there are&#xD;
        any questions as to the inclusion or exclusion of a particular patient, please contact the&#xD;
        study Medical Monitor.&#xD;
&#xD;
          1. Pregnancy or lactation&#xD;
&#xD;
          2. Body mass index at screening &lt;18 or &gt;30 kg/m2&#xD;
&#xD;
          3. Clinically significant intestinal adhesions and/or chronic abdominal pain that can&#xD;
             interfere with the conduct of the study&#xD;
&#xD;
          4. Active Crohn's disease or IBD (as evaluated by standard procedures employed by the&#xD;
             investigator/institution). If in remission, must be ≥12 weeks of remission prior to&#xD;
             screening&#xD;
&#xD;
          5. Inflammatory bowel disease patients who have NOT been on a stable drug treatment&#xD;
             regimen for at least the past 3 months prior to screening&#xD;
&#xD;
          6. Visible blood in the stool within the last 3 months&#xD;
&#xD;
          7. Known heart failure or active coronary disease&#xD;
&#xD;
          8. Alcohol or drug abuse within the last 12 months by history, or a disqualifying&#xD;
             positive urine drug test at screening.&#xD;
&#xD;
          9. Inadequate renal function as defined by serum creatinine &lt;0.7 or &gt;1.3 mg/dL (in men)&#xD;
             and &lt;0.6 or &gt;1.1 mg/dL in women.&#xD;
&#xD;
         10. Personal or family history of medullary thyroid cancer.&#xD;
&#xD;
         11. History of pancreatitis&#xD;
&#xD;
         12. Any use of growth hormone, or growth factors such as native GLP-2 or GLP-2 analog&#xD;
             (teduglutide) within the last 3 months&#xD;
&#xD;
         13. Use of antibiotics within the last 30 days&#xD;
&#xD;
         14. Patient not capable of understanding or not willing to adhere to the study visit&#xD;
             schedules and other protocol requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary E Layton</last_name>
    <phone>919-275-1933</phone>
    <email>SBS1002@9meters.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Short Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

